Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05156398 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Name: Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — clinical trial record (NCT05156398)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorPfizer

Started2022-02-28

View on ClinicalTrials.gov ↗

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.

Amendment history 3 changes detected by DataLookout

2026-08-25

Trial sites expanded: 90 → 93 locations

2026-05-12

Trial sites expanded: 44 → 90 locations

2026-05-06

Trial sites reduced: 90 → 44 locations

Trial Details

NCT Number	NCT05156398
Lead Sponsor	Pfizer
Conditions	Migraine
Enrollment	640 participants
Start Date	2022-02-28
Primary Completion	2031-11-29 (estimated)
Study Completion	2032-11-27 (estimated)
Updated on ClinicalTrials.gov	2026-08-24